Yahoo · Sep 16, 2026
What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?
Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the CD228V candidate across multiple human disease areas. Pfizer retains economic participation through financial milestones, royalties and ongoing involvement in the CD228V development program. This new Pfizer Medicus CD228V antibody-drug conjugate partnership...

